BridgeBio Pharma (NASDAQ: BBIO) insider transactions

In the twelve months to 10 November 2026, executives and directors of BridgeBio Pharma reported 141 open-market sales of 1,330,520 shares ($96.3m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in BridgeBio Pharma shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
30 October 2026	Apuli Maricel	Chief Accounting Officer	Open-market sale, 10b5-1 plan	−2,000	$72.85	120,687	Form 4
17 September 2026	Kumar Neil	Chief Executive Officer	Open-market sale, 10b5-1 plan	−8,721	$69.01	496,965	Form 4
17 September 2026	Kumar Neil	Chief Executive Officer	Open-market sale, 10b5-1 plan	−1,279	$69.57	495,686	Form 4
19 August 2026	Kumar Neil	Chief Executive Officer	Open-market sale, 10b5-1 plan	−8,100	$83.86	507,586	Form 4
19 August 2026	Kumar Neil	Chief Executive Officer	Open-market sale, 10b5-1 plan	−1,800	$84.69	505,786	Form 4
19 August 2026	Kumar Neil	Chief Executive Officer	Open-market sale, 10b5-1 plan	−100	$85.65	505,686	Form 4
18 August 2026	Kumar Neil	Chief Executive Officer	Open-market sale, 10b5-1 plan	−1,900	$81.15	276,407	Form 4
18 August 2026	Kumar Neil	Chief Executive Officer	Open-market sale, 10b5-1 plan	−17,279	$82.21	259,128	Form 4
18 August 2026	Kumar Neil	Chief Executive Officer	Open-market sale, 10b5-1 plan	−14,602	$82.99	244,526	Form 4
18 August 2026	Kumar Neil	Chief Executive Officer	Open-market sale, 10b5-1 plan	−1,199	$83.77	243,327	Form 4
16 August 2026	Apuli Maricel	Chief Accounting Officer	Shares withheld for tax	−4,714	$79.86	122,687	Form 4
16 August 2026	Kumar Neil	Chief Executive Officer	Option exercise	+33,544	—	276,871	Form 4
16 August 2026	Kumar Neil	Chief Executive Officer	Option exercise	+19,599	—	296,470	Form 4
16 August 2026	Kumar Neil	Chief Executive Officer	Option exercise	+11,554	—	308,024	Form 4
16 August 2026	Kumar Neil	Chief Executive Officer	Option exercise	+6,520	—	314,544	Form 4
16 August 2026	Kumar Neil	Chief Executive Officer	Shares withheld for tax	−36,237	$79.86	278,307	Form 4
16 August 2026	Trimarchi Thomas	President and CFO	Shares withheld for tax	−22,781	$79.86	336,529	Form 4
30 July 2026	Apuli Maricel	Chief Accounting Officer	Open-market sale, 10b5-1 plan	−2,000	$80.06	127,401	Form 4
9 July 2026	Cook Jennifer E.	Director	Option exercise, 10b5-1 plan	+19,000	$8.45	27,383	Form 4
9 July 2026	Cook Jennifer E.	Director	Option exercise, 10b5-1 plan	+112,422	$29.00	139,805	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the BridgeBio Pharma page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.